Cancer Biomarkers Market
Cancer Biomarkers Market (Test Type - PSA Tests, CTC Tests, AFP Tests, CA Tests, HER2 Tests, BRCA Tests, ALK Tests, CEA Tests, EGFR Mutation Tests, and KRAS Mutation Tests; Disease Indication - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Blood Cancer, Prostate Cancer, Ovarian Cancer, Stomach Cancer, and Liver Cancer) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
Press Release :
Cancer Biomarkers Market - Snapshot
The rising prevalence of cancer worldwide is pertaining to the improvement in healthcare infrastructure and development in medical facilities. Biomarkers have come to assume essential part across all phase of disease care, and are on the way to get disguised in routine clinical consideration. In the course of recent years, steps in the disease biomarkers market have improved location of malignant growth in different populace accomplices. Biomarkers in oncology alongside the combination of new advancements to distinguish them are crucial in the administration of different disease types.
Among the various cancer types, the lung cancer type was the most common in 2016 owing to its high mortality rates. This propelled rapid advancement in assays, and lung screening programs. The arising cluster of biomarkers in cellular breakdown in the lungs screening programs in created world to deal with the disease is a key pattern supporting the segmental development. Patients with little cell cellular breakdown in the lungs (SCLC) is additionally liable to profit by the utilization of malignancy biomarkers in anticipation. However, breast cancer type is likely to gain impetus in the coming years.
The worldwide pandemic of the novel coronavirus had a slight effect on the cancer biomarket market in terms of diagnostic urgency. Major medical research institutes were engrossed in the development of antivirus to fight the COVID-19 pandemic. However, the number of cancer cases is still on a surge, indicating huge scope of growth for both the market and its players.
Major manufacturers of cancer biomarkers are focusing on research and development of better therapeutics to gain a competitive edge in the overall market. Heavy investment on this research and development will bode well for the market in the coming years. The growing geriatric population, coupled with the rising prevalence of various cancer types will further add impetus to the growth of the market in the long run.
Cancer Biomarkers Market: Scope
Biomarkers in oncology along with the assortment of new technologies to identify them are vital in the management of various cancer types. The potential in cancer biomarkers market is varied: risk assessment, population-based screening, prognosis, treatment response, and progression of disease. Biomarkers have come to play crucial role across all stage of cancer care, and are on the path to become internalized in routine clinical care. Over the past few years, strides in the cancer biomarkers market have improved detection of cancer in various population cohorts. A wide range of tests include prostate-specific antigen (PSA) tests, Circulating-Tumour-Cells (CTC) tests, AFP tests, CA tests, HER2 tests, BRCA tests, ALK tests, CEA tests, EGFR mutation tests, and KRAS mutation tests. Analysts and experts tracking the development of biomarkers for new and emerging cancer find interesting dynamics in the cancer biomarkers. These dynamics help in understanding how they have shaped the management of cancer in world. Players have thrown their weight behind in establishing clinical validity.
Cancer Biomarkers Market: Evolutionary Dynamics
Cancer biomarkers are developed to meet the needs of multiple clinical settings. The key cornerstone for development of cancer biomarkers is establishing its analytical validity. Reduction in death rates in most of the cancer has declined over the last ten years in the developing and developed world, particularly in case of breast and colorectal cancer. On the other hand, few cancer has seen constantly declining death rate. Nevertheless, the morbidity of cancer is huge, stimulating relentless research and development of new technologies to identify biomarkers. This is a key factor underpinning the expansion of the cancer biomarkers market. but also in identifying pre-cancerous patients.
The global cancer biomarkers market stood at US$10.25 bn in 2016, and is projected to touch valuation of US$27.63 bn by 2025-end. The global market is expected to clock CAGR of 11.8% from 2017 to 2025.
Segmentation and Promising Segments:
A better understanding of the emerging avenues and current opportunities in the cancer biomarkers market, the study segments it on the basis of: test type, disease indication, and region.
High Mortality of Lung Cancer Spur Growth in Segment
The key disease indications in the cancer biomarkers market comprise the segments of breast cancer, lung cancer, colorectal cancer, melanoma, blood cancer, prostate cancer, ovarian cancer, stomach cancer, and liver cancer. Of all, the opportunities in the lung cancer is most 2016. The mortality is markedly higher than all others—per the American Cancer Society, it amounts to 25% of all cancer deaths, combining men and women populations. This has called for swift advancements in assays, thereby fueling the growth of the cancer biomarkers market. The emerging array of biomarkers in lung cancer screening programs in developed world to manage the cancer is a key trend bolstering the segmental growth. Patients with small cell lung cancer (SCLC) is also likely to benefit from the use of cancer biomarkers in prognosis.
Utilization of CTC in Early Carcinogenesis Stokes Its Popularity
Of the various types of tests, CTC accounted for the leading share in the cancer biomarkers market in 2016. The segment is anticipated to continue its dominance streak in coming years. CTC has incredible potential as a sensitive cancer biomarker for early detection, and hence various technologies to identify CTC attract groundswell of attention of industry players and researchers alike. A reason behind the popularity of cancer biomarkers is early carcinogenesis. Various studies have indicated high potential of this biomarker in people with high smoking habits. Patient in whom CTC is detected are usually considered to be high risk cohort that needs constant monitoring. The key clinical proposition for the industry interest in use of cancer biomarkers is symptomatic men and women.
The growing demand for CTC in the cancer biomarkers market also stems from the need for various targeted therapies for various patients. They are mainly used in detection of breast, ovarian, prostate, lung, and renal cancer.
North America Top Contender
The various regional segments in the cancer biomarkers market are Asia Pacific, Europe, the Middle East and Africa, Latin America, and North America. Of these, North America held the majority of shares in 2016. The popularity of cancer biomarkers is stoked by the rising demand for these in reducing the prevalence of various types of cancer. Governments in this region are committing large-scale investments in the management of cancer. This has led to focus on early detection of cancer and also on monitoring the treatment effectiveness.
High Health Burden Makes Asia Pacific Emerging Market
Meanwhile, Asia Pacific is a promising regional market. The mortality of cancer is substantial across the region, propelling advances in the cancer biomarkers market. Often times, this is due to late detection of the cancer. As a result, there is a large unmet need for rapid assay for detecting various cancer types, especially in less developed economies.
Rapidly aging populations in numerous countries also makes them vulnerable to cancer, thus, proving to a be lucrative avenue for players seeking new revenue streams in the cancer biomarkers market.
Some of the prominent players in the cancer biomarkers market are BioMérieux, Genomic Health, Inc., Novartis AG, Merck & Co., Inc., QIAGEN, Agilent Technologies, Illumina, Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., and Abbott Laboratories.
Global Cancer Biomarkers Market: Overview
Biomarkers are the substance or molecules found in blood, other body fluids or tissues which states the normal and abnormal condition of the body, biomarkers helps to detect various diseases such as cancer. Cancer biomarkers tests are carried out to detect genes or mutated genes responsible for cancer. Dramatic improvement in the cancer biomarkers tests will increase demand globally.
A detailed overview of market dynamics, including the drivers, restraints, and opportunities of the cancer biomarkers market, has been provided in this report. Market revenue for all the above mentioned segments, and their sub segments has been provided for the forecast period of 2017-2025, considering 2016 as the base year, and 2015 as the historical year, along with compound annual growth rate (CAGR %), for the forecast period of 2017-2025. Market share estimations were based on in-depth analysis and study of products, and their features, prices etc.
This report provides in-depth analysis of the cancer biomarkers market. The stakeholders for this report include companies involved in the reagent manufacturer for cancer biomarkers tests. For providing a snapshot of this market to the stakeholders, executive summary section is included in this report, which summarizes the market size, trends and competition in different regions. Market share analysis among the market players is analyzed to signify percentage share of the major players operating in the cancer biomarkers market. Furthermore, the report incorporates market attractiveness analysis by geography that depicts the most attractive and significant region in the global market in 2015.
The research methodology is a combination of primary and secondary research. Primary research includes information collected via e-mails, and telephonic interviews of Key Opinion Leaders (KOL), and forms the bulk of our research. Secondary research includes information collected from various sources, by study of company websites, annual reports, stock analysis presentations, press releases, and various national and international databases.
Global Cancer Biomarkers Market: Segmentation
Based on test type, global cancer biomarkers market are segmented into PSA tests, CTC tests, AFP tests, CA tests, HER2 tests, BRCA tests, ALK tests, CEA tests, EGFR Mutation tests, KRAS Mutation tests and others. Based on disease indication, the cancer biomarkers market are segmented into breast cancer, lung cancer, colorectal cancer, melanoma, blood cancer, prostate cancer, ovarian cancer, stomach cancer, liver cancer and others.
Based on geography, the cancer biomarkers market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The regions are further segmented into major countries which include, U.S., Canada, Germany, U.K., France, Spain, Italy, Russia, rest of Europe, India, China, Japan, Australia and New Zealand, Rest of Asia Pacific, Brazil, Mexico, Rest of Latin America, GCC countries, South Africa and Rest of Middle East and Africa.
Companies Mentioned in the Report
The report also comprises list major players in the market, their SWOT analysis, market share of these players in the cancer biomarkers, key business strategies, product portfolios, and recent developments. Key market players profiled in this report include, Abbott Laboratories, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, QIAGEN, Merck & Co., Inc., Hologic, Inc., Novartis AG, bioMérieux SA, Genomic Health, Inc. and others
The global cancer biomarkers market has been segmented as follows:
by Test Type
by Disease Indication